Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.

Onal C., Kose F., Ozyigit G., Aksoy S., Oymak E., Muallaoglu S., ...More

The Prostate, vol.81, pp.543-552, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 81
  • Publication Date: 2021
  • Doi Number: 10.1002/pros.24132
  • Journal Name: The Prostate
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.543-552
  • Keywords: abiraterone, enzalutamide, oligometastasis, prostate cancer, stereotactic radiotherapy, MITOXANTRONE PLUS PREDNISONE, ABIRATERONE ACETATE, INCREASED SURVIVAL, RADIATION-THERAPY, DOUBLE-BLIND, ENZALUTAMIDE, DOCETAXEL, PROGRESSION, CHEMOTHERAPY, DECLINE
  • Hacettepe University Affiliated: Yes

Abstract

Background Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA) treatment. We evaluated prognostic factors for prostate cancer-specific survival (PCSS) and progression-free survival (PFS) to characterize patients receiving treatment with ARTA who may benefit from MDT for oligoprogressive lesions. The impact of MDT on delaying NEST and the predictive factors for NEST-free survival (NEST-FS) were also assessed.